1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Valuation
Discussion
Symbol
NVCT
Event Date
2022-02-04
Sector
Health Care
Subsector
Pharmaceuticals
Offer Range
$5.00
Shares Offered
3.2M
12.72M
$69.6M
25.2%
Implied Upside vs Midpoint
Description
We are a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology. We rely on our core competencies of target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs. Improved genetic sequencing and understanding of cancers’ RNA, DNA and protein abnormalities has led to the discovery and characterization of novel oncogenic genetic mutations and alterations that were previously unknown, unaddressed, unsuccessfully targeted or overlooked. We believe that these advancements represent a fundamental change in the development of targeted therapies and will increasingly lead to tumor agnostic approaches whereby cancers will be characterized for treatment based on genetic signatures, such as a certain mutation, rather than in a tissue-specific manner. We are currently developing two drug candidates: NXP800, which commenced a Phase 1 clinical trial in December 2021 and NXP900, which is in preclinical development. With our precision medicine approach, we aim to pharmacologically target novel oncogenic pathways which are key drivers of the disease. As such, we believe that our approach can also enable the use of biomarker-based patient selection, wherein patients are selected for treatment with a drug based on specific attributes of their cancer, such as specific mutations and cellular alterations. Our approach could prospectively identify patients that are more likely to benefit from our targeted therapy, which is a type of treatment that precisely identifies and attacks a specific pathway of cancer cells, thereby potentially increasing the likelihood of a successful treatment outcome. We have extensive experience and expertise in licensing promising product candidates from a wide range of global sources, including universities, academic/research centers and biotechnology companies. In May 2021, we licensed exclusive worldwide commercial rights to NXP800, an HSF1 pathway inhibitor, our lead product candidate, which was discovered and developed in the drug discovery program at the Institute for Cancer Research (“ICR”) in London, England. The ICR performs pioneering work in discovering new cancer drugs with unique mechanisms of action. The ICR’s drug discovery unit has discovered several successful clinical drug candidates, the most notable of which is Zytiga, a leading drug for metastatic prostate cancer. In August 2021, we licensed worldwide commercial rights to NXP900, a novel SRC/YES1 kinase inhibitor from the University of Edinburgh, Scotland, U.K. (“UoE”). UoE is considered a leader in research designed to discover novel targeted-therapy drug candidates. Our license agreements for NXP800 and NXP900 are subject to certain milestone and royalty payments. In December 2021, we announced the commencement of the Phase 1 study for NXP800. The Phase 1 study will have two parts: dose-escalation Phase 1a, initiated in December 2021, followed by an expansion Phase 1b. In the Phase 1a, the safety and tolerability of NXP800 will be evaluated in patients with advanced solid tumors to identify a dose and dosing schedule for the Phase 1b. The Phase 1a is being conducted in the U.K. In the Phase 1b, the safety and preliminary anti-tumor activity of NXP800 will be evaluated in biomarker-selected patients, initially in ovarian clear cell carcinoma and endometrioid carcinoma. The Phase 1b is expected to be conducted in the U.K. and the U.S. Our drug candidates have not yet been approved by the U.S. Food and Drug Administration (“FDA”), and we may not obtain FDA approval for any of our drug candidates. --- We were incorporated in July 2020 under the laws of the State of Delaware under the name Centry Pharma, Inc., and changed our name to Nuvectis Pharma, Inc. in July 2021. Our principal executive offices are located at 1 Bridge Plaza, 2nd Floor, Fort Lee, NJ 07024, and our telephone number is (201) 614-3150. Our website address is www.nuvectis.com.
Nuvectis Pharma, Inc. annual income statement and balance sheet, FY 2021 to FY 2025, as reported in SEC filings.
| Metric | FY 2021 | FY 2022 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Operating income | ($12.9M) | ($19.2M) | ($19.8M) | — |
| Net income | ($12.9M) | ($19.1M) | ($19.0M) | — |
| Metric | FY 2021 | FY 2022 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Total assets | $6.7M | $20.4M | $18.6M | $31.7M |
| Total liabilities | $2.4M | $6.2M | $8.9M | $13.3M |
| Total equity | ($11.0M) | $14.2M | $9.7M | $18.4M |
| Cash & equivalents | $5.7M | $20.0M | $18.5M | $31.6M |